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ABSTRAK
Laporan ini merupakan laporan pertama mengenai kejadian resistensi obat HIV di RSUPN Dr. Cipto 
Mangunkusumo. Kami melakukan uji deteksi resistensi obat HIV pada 11 pasien HIV kasus baru yang 
mengalami gagal virologi setelah dilakukan pengobatan antiretrovirus lini pertama selama 6 bulan. Dengan 
metode sekuensing, dilakukan analisis mutasi gen penyandi resistensi obat HIV. Subtipe HIV-1 serta hasil uji 
resistensi secara genotip diinterpretasi menggunakan database Stanford DR. Dari sepuluh sampel plasma 
yang berhasil diamplifikasi dan disekuensing, ditemukan resistensi secara genotipik. Berdasarkan rejimen 
antiretrovirus yang diterima, ditemukan manifestasi resisten terhadap rejimen lamivudine (90%), tenofovir 
(83%), nevirapine (100%) dan efavirenz (100%). Menarik untuk diperhatikan bahwa tidak ditemukan manifestasi 
resistensi terhadap zidovudine, termasuk pada empat pasien HIV/AIDS yang mendapatkan zidovudine dalam 
rejimen terapinya. Mutasi NRTI yang banyak ditemukan adalah M184VI dan K65R, sedangkan mutasi NNRTI 
adalah Y181CFGVY, K103N, A98AG, E138GQ dan G190AGS. Tidak ditemukan mutasi mayor terhadap PI. 
Berdasarkan temua tersebut, memperkuat urgensi monitoring virologi, survey resistensi obat HIV serta akses 
pilihan terapi yang sesuai pada kasus gagal terapi.
Kata kunci: resistensi obat HIV, gagal virologi, HIV-1.
ABSTRACT
This is the first report of HIV drug resistance in RSUPN Dr. Cipto Mangunkusumo. We reviewed eleven 
new cases of HIV patients who had virologic failure after 6 months first-line antiretroviral therapy. With the 
sequencing method, analysis of gene mutations encoded HIV drug resistance. Genotypic resistance results and 
HIV-1 subtype were interpreted by Stanford DR database. Of ten plasma samples that were successfully amplified 
and sequenced, all samples were resistant to at least one antiretroviral drug. Genotypic resistance towards the 
antiretroviral drugs being used was observed in lamivudine (90%), tenofovir (83%), nevirapine (100%) dan 
efavirenz (100%). It is interesting that no zidovudine resistance were found, including in four patients receiving 
zidovudine in their HAART. The common NRTI mutations were M184VI and K65R, while NNRTI mutations were 
Y181CFGVY, K103N, A98AG, E138GQ and G190AGS. No mayor PI mutations were found. Based on these 
findings, we supports the need for appropriate virology monitoring and HIV drug resistance survey in clinical 
practice and access to drug options in case of virology failure.
Keywords: HIV drug resistance, virologic failure, HIV-1.
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INTRODUCTION
The first case of HIV infection in Indonesia 
was detected in 1987 and by the end of 2013, 
about 120.000 people were reported living with 
HIV.1 Several programs were introduced to 
combat HIV/AIDS, including providing highly 
active antiretroviral therapy by the Ministry 
of Health. The coverage of antiretroviral 
therapy was estimated to be around 30% 
(39.418/12.000).1
The increasing number of people with access 
to ART has resulted in substantial declines in 
HIV related incidence, morbidity and mortality. 
However, the widespread of antiretroviral 
therapy have consequences in mutation and 
selection process. The large mutation number 
of HIV-1 was also affected by the absence of 
a proofreading mechanism and the high rate of 
replication virus.2 Drug resistant mutations can 
lead to decreasing susceptibility to some anti-
retroviral drugs, poor treatment response and 
cause failure therapy.2
In well-resourced settings, clinical guidelines 
recommend that resistant testing be done 
before administration of antiretroviral therapy 
and evaluated every 6 months.3 However, in 
Indonesia, routine virological monitoring and 
resistant testing were not recommended yet. 
The lack of examination access was associated 
with accumulation of resistance mutations, 
limiting future therapeutic choices. Moreover, 
these resistant viruses could be a source of new 
resistant cases transmission.
Currently, only a few studies have described 
the epidemiology of drug resistant HIV among 
treatment-exposed patients. There is no study 
reporting the mutations patterns of HIV among 
failing patients. The present study assessed HIV 
drug resistance in patients with virologic failure 
to obtain an overview of resistance condition, 
as well as raise awareness of the transmission 
of HIV-1 strains resistant.
CASE ILLUSTRATION
Eleven new cases of HIV in the period from 
September 2013 to March 2014, were found to 
have failed therapy. Virologic failure was defined 
as a viral load >200 copies/ml after receiving 
6 months first-line antiretroviral therapy. Most 
patients were male (54,6%) and heterosexual 
contact (54,6%) were the predominant route 
of transmission. All patients were receiving 
two nucleoside reverse transcriptase inhibitors 
(NRTIs) plus one non-nucleoside reverse 
transcriptase inhibitor (NNRTI). Combination of 
3TC/TDF/EFV was the common regimen being 
used (36,3%). (Table 1)
Resistance testing of plasma virus was 
conducted at the Institute of Human Virology and 
Cancer Biology laboratory. Genotyping of HIV-1 
pol region, especially the region coding protease 
and reverse transcriptase, was undertaken in 
plasma specimens using in house sequencing 
methods.
Table 1. Demographical and clinical data of patients
Pts No. Sex/Age Trans Route OI ARV CD4 M-0 CD4 M-6 VL
1 M/30 MSM TB 3TC, AZT, NVP 52 164 43,500
2 M/31 IVDU TB; Hep B 3TC, TDF, EVF 25 11 195,000
3 M/29 IVDU TB 3TC, TDF, EFV 4 20 232,000
4 F/31 HS None 3TC, AZT, NVP 27 118 106,000
5 M/32 IVDU Hep C 3TC, TDF, NVP 21 6 104,000
6 F/27 HS TB 3TC, TDF, EVF 67 157 33,200
7 F/30 HS Hep C 3TC, TDF, NVP 33 38 33,900
8 F/32 HS None 3TC, TDF, EFV 100 127 326,595
9 M/35 Unclear None 3TC, AZT, NVP 166 274 385
10 F/25 HS TB 3TC, AZT, EFV 63 114 6,180
11 M/32 HS TB 3TC, TDF, EFV 47 150 126,000
OI: Opportunistic infection; ARV: Antiretroviral Regimens; M-0: month 0; M-6: month 6; VL: viral load; MSM: Male sex with 
male; IVDU: Intravenous drugs user; HS: heterosexual contact; 3TC: Lamivudine; AZT: Zidovudine; NVP: Nevirapine; 
TDF: Tenofovir; EVF: Evafirenz
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Antiretroviral drug resistance mutations 
(DRM) were identified and interpreted using the 
Standford HIVdb genotypic resistance algorithm. 
HIV-1 drug susceptibility was categorized as 
susceptible, potential low-level resistance, 
low-level resistance, intermediate resistance, or 
high-level resistance.
Genotypic Resistance Test
Of the 11 participants with HIV RNA 
>200 copies/ml, ten samples were successfully 
amplified and sequenced. The major HIV subtype 
in this study was CRF01_AE. All samples 
had at least one major drug resistant mutation 
(DRM), especially major mutation related with 
NNRTI resistance. One patient who has no major 
NRTI mutation was infected by HIV-1 subtype 
C. Overall, the number of NNRTI-associated 
resistance mutations were higher than NRTI-
associated resistance mutations. Three viral 
strains from patients were resistant to all received 
drugs, six viral strains were resistant to two of 
the drugs constituting HAART, whereas one viral 
strain resistant only resistant to one regimen that 
was accepted. 
The most prevalent NRTI mutations were 
M184V (n=9), followed by K65R (n=4) and 
K70EK (n=2). One patient had HIV-1 strain with 
reverse thymidine analog mutation (TAMs). The 
major NNRTI mutations were Y181C (n=5) and 
K103N (n=4), followed by G190AG/S (n=3) and 
K101E (n=2). No major PI associated resistance 
mutations were found. (Table 2)
Antiretroviral Resistance Levels
Based on Standford HIVdb genotypic 
resistance algorithm, high-level resistance was 
seen in all NRTI and NNRTI regimens, except 
zidovudine. The level of resistance was more 
varied to the NRTIs than NNRTIs. Observed 
profiles included not only to regimens consumed 
and available in Indonesia but also other NRTIs 
and NNRTIs that were not included in prescribed 
regimens as didanosine and etravirine. The 
distribution of high-level resistance among the 
study participants were resistance to nevirapine 
(10/10), lamivudine (9/10), abacavir (9/10), 
efavirenz (8/10), stavudine (5/10), emtricitabine 
(5/10), tenovofir (4/10), rilpivirine (3/10), 
didanosine (1/10), and etravirine (1/10). (Figure 
1)
DISCUSSION
The population of our study is probably 
quite representative of the global population 
of HIV-infected patients in Indonesia. The data 
clearly demonstrate the predominance of HIV-1 
CRF01_AE. In similar with other studies, this 
result indicates that CRF01-AE has stabilized 
its predominance in Indonesia.4-6
The predominance of the M184V, Y181C 
and K103N mutations was expected to occur due 
to the use of standard first-line regimens which 
are lamivudine for the NRTIs and nevirapine 
or efavirenz as NNRTI regimens. The M184V 
mutation selected by the use of 3TC has been 
Table 2. Distribution of ARV associated resistance mutations
Patients 
No ARV Regimens Subtype NRTI mutation NNRTI mutation PI mutation
1 3TC, AZT, NVP CRF01_AE M184V A98AG, Y181CY, G190AG, H221HY -
2 3TC, TDF, EFV CRF01_AE D67N, K70E, M184V K101E, E138G, G190S -
3 3TC, TDF, EFV CRF01_AE L74LV, Y115FY, M184V K101E, E138Q, G190S L10V
4 3TC, AZT, NVP CRF01_AE M184V Y181C -
5 3TC, TDF, NVP CRF01_AE K65R, M184V A98AG, K103N, Y181C L10I
6 3TC, TDF, EFV CRF01_AE K65R, M184I V90I, K103N, Y181C -
7 3TC, TDF, NVP CRF01_AE A62AV, K65KR, M184I Y181CFGV -
8 3TC, TDF, EFV C K70EK K103N, P225HP -
9 3TC, AZT, NVP Amplification failure
10 3TC, AZT, EFV CRF01_AE M184I K103N, P225HP -
11 3TC, AZT, EFV CRF01_AE K65R, M184V, T215S A98G, L100I, V108I -
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found in similar setting in which 3TC included 
in the first-line antiretroviral regimens.7-9 Y181C 
mutation occurred in nevirapine containing 
therapy, while K103N mutation occurred more 
frequently in efavirenz containing therapy. These 
mutations were also reported by several studies 
in another country.8,10-12
The K65R mutation was commonly observed 
in patients who failed a tenofovir-containing 
regimens. The relatively high proportion of 
K65R mutation exceeds the estimated rate 
in accordance with other reports.13-15 It was 
probably caused by shifting in therapeutic 
regimen selection since tenofovir is expected to 
be a substitute of thymidine analog regimens. 
This result need to be criticized and studied 
further to ensure the efficacy of tenofovir and 
its potency in causing resistance.
Limited TAMs were observed in this study 
and no zidovudine associated TAMs were found. 
This is in contrast with data reported by Marconi 
(2008), Gupta (2009) and Pham (2013).11,16,17 
This event may be explained by the fact that 
most of HIV-1 subtype in the present study was 
subtype CRF01_AE, whereas other studies were 
dominated by subtype B as well as mutations 
encoding resistance standards used today are 
based on mutations that occur in subtype B.18,19 
Some studies have reported that non-B HIV-
1 have natural polymorphism that affect its 
susceptibility, but there is no recent studies on 
the incidence of HIV-1 subtype CRF01_AE 
polymorphism and its association with resistance 
to zidovudine. Other causes are thought to have 
a role is because of the high level of the M184V 
mutation that gives the opposite effect to the 
workings of thymidine analogues. Similar to 
other studies, this finding suggested that TAMs 
takes a longer time to develop compared with 
M184V and NNRTI-associated mutations.
The combination of K101E, E138G, G190S 
mutations were found in two patients, while one 
case of G190S mutations were found in other 
combination. The G190S mutation was non-
polymorphic mutation that selected by nevirapine 
and efavirenz and is one of NNRTI resistance 
mutation most commonly found.8,11,12 The K101E 
mutation is minor mutation encoding all regimens 
of NNRTI resistance.20 This mutation was selected 
by nevirapine and efavirenz, in appropriate with 
the available regimens. The E138Q/G mutation 
is generally selected by etrivirine and rilpivirine, 
regimens that are not used in this study. The 
finding of this mutation was suggested that 
mutations could occur spontaneously, not only 
due to the pressure of the treatment.
In our study, no PI associated resistance 
mutations were identified. This finding affirms 
that PI is still viable as second-line therapy in 
Indonesia.
Figure 1. Distribution of antiretroviral resistance level
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CONCLUSION
This case series demonstrates the potential 
of HIV drug resistance in patients with virologic 
failure after 6 months therapy. The most common 
mutations were associated with NRTI and 
NNRTI resistance, respectively. HIVDR testing 
should be considered in all virologic failure cases 
to prevent unnecessary/premature switches.
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